专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09603840B2 Treatment using dantrolene 有权
公开(公告)号：US09603840B2
公开(公告)日：2017-03-28
申请号：US14950571
申请日：2015-11-24
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415 , A61K31/4178 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

2. 发明申请

US20160074366A1 TREATMENT USING DANTROLENE 审中-公开
标题翻译：使用DANTROLENE治疗
公开(公告)号：US20160074366A1
公开(公告)日：2016-03-17
申请号：US14950571
申请日：2015-11-24
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/16 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

3. 发明申请

US20190255021A1 TREATMENT USING DANTROLENE 审中-公开
公开(公告)号：US20190255021A1
公开(公告)日：2019-08-22
申请号：US16397176
申请日：2019-04-29
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/16 , A61K9/10 , A61K9/00 , A61K9/19 , A61K47/18 , A61K47/10 , A61K9/127
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

4. 发明申请

US20140099382A1 TREATMENT USING DANTROLENE 审中-公开
标题翻译：使用DANTROLENE治疗
公开(公告)号：US20140099382A1
公开(公告)日：2014-04-10
申请号：US14103546
申请日：2013-12-11
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

5. 发明申请

US20210015796A1 TREATMENT USING DANTROLENE 有权
公开(公告)号：US20210015796A1
公开(公告)日：2021-01-21
申请号：US17064693
申请日：2020-10-07
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/00 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K9/19
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

6. 发明申请

US20160243083A1 TREATMENT USING DANTROLENE 审中-公开
公开(公告)号：US20160243083A1
公开(公告)日：2016-08-25
申请号：US15144124
申请日：2016-05-02
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

7. 发明授权

US09271964B2 Treatment using dantrolene 有权
公开(公告)号：US09271964B2
公开(公告)日：2016-03-01
申请号：US14103546
申请日：2013-12-11
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415 , A61K31/4178 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

8. 发明授权

US09884044B2 Treatment using dantrolene 有权
公开(公告)号：US09884044B2
公开(公告)日：2018-02-06
申请号：US15406237
申请日：2017-01-13
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/16 , A61K9/00 , A61K9/19 , A61K9/10
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

9. 发明授权

US09789090B2 Treatment using dantrolene 有权
公开(公告)号：US09789090B2
公开(公告)日：2017-10-17
申请号：US15144124
申请日：2016-05-02
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415 , A61K31/4178 , A61K9/127 , A61K47/10 , A61K47/18 , A61K9/10 , A61K9/16 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

10. 发明申请

US20170143677A1 TREATMENT USING DANTROLENE 审中-公开
公开(公告)号：US20170143677A1
公开(公告)日：2017-05-25
申请号：US15406237
申请日：2017-01-13
申请人： Lyotropic Therapeutics, Inc.
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/10 , A61K9/19 , A61K9/16 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式